Image used for representational purpose only. | Reuters 
Business

Strides Shasun gets USFDA approval for generic anti-allergy capsules

The Bengaluru-based pharma company said the US market for cetirizine hydrochloride capsules is approximately USD 60 million, with only one other generic player.

From our online archive

NEW DELHI: Strides Shasun today said it has received approval from the US Food and Drug Administration for cetirizine hydrochloride capsules, used to relieve allergy symptoms.

In a BSE filing, Strides Shasun said, "It has received approval from the US FDA for cetirizine hydrochloride capsules, 10mg (liquid filled capsules OTC)".

The company said the product will be manufactured at its facility in Bengaluru and is ready for launch.

Quoting IRI data, Strides Shasun said the US market for cetirizine hydrochloride capsules is approximately USD 60 million, with only one other generic player.

Shares of the company were trading 0.16 per cent higher at Rs 1,081.20 on BSE.

Sunetra Pawar takes oath as Maharashtra's first woman deputy Chief Minister

Growth with livelihoods: Six ways the budget can rethink its priorities

Elena Rybakina wins Australian Open by beating No. 1 Aryna Sabalenka for her 2nd Grand Slam title

BJP will come to power in Bengal, corrupt people will be sent to jail one after another: Amit Shah

C J Roy suicide: Karnataka Home Minister orders police probe into circumstances leading to death

SCROLL FOR NEXT